Compare Becton Dickinson and Co (BDX) vs Core Scientific Inc (CORZ) Price & Performance

BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.

The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.

Core Scientific (CORZ) trades at $21.01, down 0.19% on the day, with technical indicators showing a bearish trend despite neutral oscillators. The company reported Q2 2026 revenue growth but missed earnings expectations with a significant net loss of -$1.4 billion for 2026. Recent news highlights a major partnership with AMD for AI infrastructure development, potentially driving future revenue growth through colocation services.

While analyst consensus remains strongly bullish with an 86% buy rating and $35.88 price target, fundamental risks include persistent negative profit margins and substantial cash burn. The AMD partnership offers significant upside potential, but investors must weigh execution risks against the company's current unprofitability and competitive pressures in the data center market.